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1. Introduction
The following chapter deals with the clinical management of mental and behavioural disorders
that may occur in patients with chronic viral hepatitis C during alpha-interferon therapy.
Actually, in clinical experience, psychopharmacological and psychological interventions are
frequently found in patients with HCV-related chronic hepatitis. These interventions are often
requested by clinicians with hepatologic and infectious diseases competence, who deliver the
ambulatory care for the treatment of interferon in general hospitals.
These interventions are always complex due to several reasons:
a. they are multidisciplinary interventions that require a great collaboration between all
specialists involved and high patients management skills.
The clinician has to deal with complex and multi-problematic situations for both the under‐
lying disease and its complications and both the onset of psychiatric disorders, especially
anxiety and depressive symptoms. Psychotic symptoms are occasional, instead.
b. there are no specific treatment guidelines for mental disorders related to chronic viral
hepatitis. Therefore, the management of these patients can be different according to the
internal organization of a psychiatric service and to the one of the general hospital that
rarely provide a specific ambulatory care for the treatment and management of psychiatric
side effects during alpha-interferon treatment.
c. The clinical picture is often blurred reported and is characterized by heterogeneous
symptoms of anxiety and depression that vary from mild to severe degree and may also
have a pejorative evolution.
© 2013 Torres et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
d. The most common criteria for psychiatric diagnosis used in the international clinical
practice and scientific research are those of the DSM IV TR [1]. This means provides
diagnostic categories whose inclusion criteria are very restrictive. Mental disorders due
to a general medical condition and substance-induced mental disorders are included in
these diagnostic categories. This last diagnostic category even includes mental disorders
induced by drugs. Nevertheless, there is no explicit reference to either HCV or interferon
therapy in both diagnostic categories.
Moreover, the underlying causes of mental disorders in patients with chronic HCV hepatitis
seem to be very complex.
In Psychiatry it is widely recognized as valid the bio-psycho-social paradigm according to
which the causes of mental illness must be found not only in genetic and constitutional reasons
but also in psychological and environmental factors. This paradigm is even more appropriate
when the mental illness and the organic illness are present at the same time.
The psychological impact of diagnosis of HCV-related chronic hepatitis, interferon treatment
and hcv neurotoxicity are definitely important in the genesis of symptoms.
2. HCV infection as life event
The  role  of  stressful  psychosocial  events  or  "life  events"  in  the  unleashing  of  psychic
pathology is  generally  accepted by most  clinicians.  As a  matter  of  fact,  it  is  difficult  to
document a causal link between life events and mental illness and it is hard to think of
a real  direct  causality between these two factors.  Some authors have proposed a model
based on a circular relationship between the event and the psychopathological manifesta‐
tion,  rather  than  a  model  based  on  a  linear  cause-effect  relationship  [2].  Available  re‐
searches,  moreover,  show that  only some individuals  will  develop a specific  psychiatric
disorder at the presence of the same life events [3].
Different regulation scales are used to define the events that can be considered as stressful and
to value their psychological burden. A personal illness, especially if chronic, is certainly an
event characterized by great emotional and psychological impact [4]. Moreover, symptoms
such as mood changes and anxiety, which are commonly observed in patients affected by HCV,
can be related to the awareness of suffering from a chronic progressive disease and to the past
or current substance abuse [5].
As we have said, the aetiology of psychiatric disorders is multifactorial and several factors can
lead to the development of the manifestations: genetic factors, evolutionary factors, environ‐
mental factors and life events. The onset of an organic diseases can lead to the outbreak of a
psychiatric disorder, not only for the psychological impact that the disease has but even due
to the changes in the immune system that can establish in certain medical conditions.
Depressive symptoms are often found in pathologies such as AIDS [6], diabetes mellitus [7],
multiple sclerosis [8] and cardiovascular disorders [9].
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3. Proinflammatory cytokines and neurotransmitter systems
It is well known that the assumption of interferon α (IFN α) is associated with the onset
of depressive symptoms, similar to those observed in major depression [10], in fact, from
30% to 50% of patients receiving IFN develop depression during treatment [11].Many da‐
ta in literature show the very important role of pro-inflammatory cytokines in the onset
of the Depression [12,13-14,15].Since the 90s, several studies have highlighted that in cer‐
tain cases the alterations of the immune system can contribute to the development of de‐
pressive  symptoms,  favouring  the  acquisition  of  new  knowledge  about  the  so-called
Psychoneuroimmunology [16].
The Neuro- Endocrine System (SNE) and the Immune System (SI) are part of a totally in‐
tegrated biological circuit, in fact, the same biochemical signals are used both for the ex‐
change  of  information  between  the  components  of  the  same  system  both  for
communications  between  the  two  systems.  Numerous  researches,  in  fact,  have  shown
that the SI is able to modify its responses, either through automatic mechanisms of regu‐
lation either  by signals  coming from the  Central  Nervous  System (CNS)  and endocrine
system (SE).  In  turn,  the  cells  of  the  SI,  sending  signals  to  the  central  nervous  system
and to the SE, trigger specific neuroendocrine and behavioural responses. Pro-inflamma‐
tory cytokines are ones of the main messengers employed by SI to communicate directly
with the  SNE,  in  particular,  they stimulate  the  activity  of  the  locus  coeruleus  (LC)  and
the hypothalamic secretion of Corticotrophin-Releasing Factor (CRF) [17].
The immune cells communicate with the SNE also by means of several neuropeptides and
neuro-hormones, such as the CRF, adrenocorticotropic hormone (ACTH), the Growth
Hormone (GH), the Thyrotropin-Releasing Hormone (TRH), prolactin, the β-endorphin, etc.;
immune cells, in fact, possess specific membrane receptors, both for these mediators both for
neurotransmitters such as adrenaline, serotonin, histamine, GABA [18].
The existence of a bi-directional network of communication between SNE and SI is extremely
important since it allows to SNE to receive and respond to a wide range of non-cognitive
stimuli, which include stresses-induced stimuli and infectious, autoimmune or neoplastic
nature-stimuli, that it could not perceive otherwise. The relationship between the nervous
system, endocrine system and immune system has been highlighted by several studies. The
baseline concentration of soluble receptors for TNF and IL-6 were linked with the development
of depression during therapy with IFN α [19]. Moreover it was found that patients suffering
from cancer and depression showed higher levels of interleukin 6 (IL6) compared to patients
affected by cancer but without depression [20]. In patients suffering from HCV, concentrations
of receptors for IL-2, IL-6 and IL-10 are significantly higher in patients who develop a depres‐
sive symptomatology during therapy with IFN, compared to patients who did not develop it.
Therefore, a greater activation of the immune system may be predictive of the development
of depression during IFN therapy [21,22].
Let's  look now at the way through pro-inflammatory cytokines,  in particular IFN α,  act
in  the  genesis  of  psychiatric  interest  symptoms.  It's  well  known  that  serotonergic  and
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dopaminergic neurotransmitter systems are involved in depressive disorders and anxiety
disorders.  In  clinical  practice,  drugs  that  act  on  the  neurotransmitter  systems  are  com‐
monly  used.  The  role  of  IFNα  in  the  development  of  depression  and  anxiety  may  be
partly due to the action on serotonin metabolism. The administration of selective seroto‐
nin  reuptake  inhibitors  (SSRIs),  in  fact,  inhibits  the  development  of  depression  in  pa‐
tients  treated  with  IFN  α  [22].  The  administration  of  paroxetine  (SSRI)  reduces  to
approximately  4  times  the  risk  of  onset  of  depression  during  therapy with  IFN α [23].
The IFNα and cytokines in general,  would contribute to the alteration of  serotonin me‐
tabolism through the activation of an enzyme called indoleamine 2-3 deoxigenase (IDO),
which  converts  tryptophan,  an  amino  acid  precursor  of  serotonin,  in  kynurenine  [24],
leading  to  a  reduction  in  the  synthesis  of  serotonin.  In  fact,  it  has  been  demonstrated
that,  patients treated with IFN α, who develop depression, have lower blood concentra‐
tions of  tryptophan [25,26].  Patients who develop major depression during IFN-α thera‐
py,  compared  with  patients  who  did  not  develop,  show  in  the  peripheral  blood
significantly reduced level  of  tryptophan and increased levels  of  kynurenine [27].  These
data would support the hypothesis according to which the reduction of levels of trypto‐
phan and, consequently the reduction of the synthesis of serotonin, are consequent to ac‐
tivation of the IDO.
Another mechanism involved in the reduction of levels of serotonin induced by cytokines is
the activation of a protein kinase, called MAPK, by themselves.
The IFNα is a potent inducer of p38 MAPK; the activation of this protein kinase increas‐
es the expression and synthesis of serotonin transporters [28,29], thus resulting in the in‐
crease  of  serotonin  reuptake,  with  consequent  reduction  of  the  neurotransmitter  in  the
synaptic cleft. Recent studies have linked the increased function of serotonin transporters
with seasonal affective disorder [30].In addition to the reduction of serotonin, alterations
in metabolism of dopamine (DA), would also contribute to the onset of symptoms such
as psychomotor retardation and fatigue. In fact, the IFN and, more generally, pro-inflam‐
matory cytokines,  act on the metabolism of DA, especially at the level of the basal gan‐
glia, causing a symptomatology characterized by neuro-vegetative symptoms, anhedonia,
psychomotor retardation, fatigue [31,32-33].
Dopamine is involved in different circuits in mood, reward and motivation, motor activity,
sleep-wake rhythm, cognitive processes [34,35].
It has been shown that IFN α induces motor slowing and this slowing down is correlated,
significantly, to the development of depression and fatigue [31].
The mechanisms by which the IFN would act resulting in a reduction of DA in the synaptic
cleft are manifold; primarily cytokines, and therefore the IFN α as well, induce an increase of
nitric oxide (NO), which causes a reduction of tetrahydrobiopterin (BH4 ) that is a co-enzyme
for tyrosine hydroxylase, which converts tyrosine to L-DOPA, this causes a reduction in the
synthesis of DA [27].
It has also been shown that the action of IFN on BH4 is mediated by nitric oxide, in fact,
treatments that inhibit the synthesis of NO, block the inhibitory effect mediated by IFN on the
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concentration, at the level of the central nervous system, of tetrahydrobiopterin ( BH4) and DA
[36]. It was also demonstrated that the IL6 (whose blood concentrations increase after admin‐
istration of IFN α), reduces the tetrahydrobiopterin at the neuronal level [37].
Another mechanism by which the IFN α works reducing the levels of DA in the synaptic cleft
involves the Kynurenic acid (KA). As we have already said, with regard to the effect of
cytokines on the metabolism of serotonin, the IFN determines an activation of the enzyme
indoleamine 2,3 dioxygenase (IDO), which cleaves the tryptophan in kynurenic acid (KA). KA
reduces the release of glutamate. The glutamate, as well known, stimulates the release of
dopamine [37,38-39]. The final effect is, in this case as well, a reduction of the levels of DA in
the synaptic cleft. Finally, the IFN α, as we mentioned above, can activate some protein kinase,
the MAPK pathway, which results in the increase in the expression of those genes coding for
transporters of DA, this causes an increased DA reuptake with consequent reduction of the
available levels of DA in the synaptic cleft [40].
It is worth pointing out that, in addition to depressive and autonomic manifestations, symp‐
toms of anxiety and irritability may also occur during therapy with IFN α.
Several studies have shown that a significant number of patients develop anxiety symptoms
1 or 2 hours after taking the interferon therapy [41]. Some neuroimaging studies have shown
that one of the mechanisms by which cytokines may cause anxiety and hyper arousal, is related
to the increased activation of neural circuits in dorsal anterior cingulate cortex [42,43].
4. Neurotoxicity of HCV
With regard to the aetio- pathogenesis the third aspect to consider is the one of specific
neurotoxicity of HCV.
In the last years it has been supposed that psychiatric disorders that occur in patients affected
by HCV are due to a direct effect of the virus.
In particular, it has been suggested that there is no link between the onset of depressive
disorders in patients with HCV infection and the IFN α- therapy [44].
An interesting study using magnetic resonance spectroscopy (MRS), a non-invasive technique
that allows to get localized biochemical information from tissues and organs, has pointed out
several alterations of cerebral metabolites in patients with HCV infection [45]. These alterations
are very similar to those caused by HIV virus which can be found in the central nervous system
during the overt disease. [46,47]. These studies support the hypothesis according to which,
even the HCV would be able to infect cells of the central nervous system, causing changes in
the brain [48]. According to this hypothesis, the virus after infecting monocytes in circulation,
is introduced into the CNS thanks to a mechanism known as "Trojan Horse," resulting in
neuronal dysfunction. This hypothesis is supported by recent studies that have demonstrated
the presence of HCV gene sequences in post-mortem examined brain tissue [49]. Another
important aspect that rises from data in literature is that different viral genotypes correlate
Chronic C Hepatitis, Interferon and Psychiatric Disorders
http://dx.doi.org/10.5772/54748
273
with a different response to the antiviral therapy with IFN-α. Up to now, according to
differences in nucleotide sequence, 7 different genotypes of HCV (in turn subdivided into
several subtypes) have been identified, with a different geographical prevalence. The most
common genotypes in Europe are 1a, 1b, 2a, 2b and 3 while in the USA is genotype 1a. Many
people believe that the genetic heterogeneity of the virus strains is the basis of the differences
in the development of disease and in the responsiveness to treatment. It is well known, in fact,
that the genotypes 1, 5 and 6 have a lower response to antiviral treatment. In particular, the
virus 1b leads to a more rapid progression to cirrhosis. In contrast, viral genotypes 2 and 3
have a better response to antiviral treatment [50].
5. Psychological aspects of the diagnosis of hepatitis C and consultation –
Liaison psychiatry
What has been argued so far gives an account of how much weight may have, in a bio-psycho-
social dimension, the diagnosis of HCV. The patient has, in fact, to live a chronic medical
condition, often without any physical and psychological resource to manage it, whose
treatment is not always effective and has serious side effects; in addition, an uncontrollable
factor, the constitutive genetic component indeed, may be decisive to a successful treatment.
The meeting with an illness, whatever it is, brings about such a big change of life to threaten
the own sense of identity so that the disease can be lived with deep anguish, hate, anxiety and
depression.
Organic disease, whatever is the form in which it may manifest, acute or chronic, mild or
severe, always represents a more or less significant break of the individual cycle of life and
therefore, it involves the psychological sphere.
Several times we have emphasized the complexity of the Psychiatrist role in patients with
HCV-related chronic hepatitis. Actually, these patients live a condition of severe insecurity,
both physical and psychological. They are forced to change their lifestyle, putting in practice
new behaviours and careful conduct rules in personal, social and relational context.
They live together with the fear of serious complications and death. The many disorders
related to hepatitis, depressive symptoms and interferon treatment, make them lose their
physical and mental energy to manage their disease condition. Typically, in fact, depres‐
sive  symptoms  reported  by  this  type  of  patients,  are  purely  somatic;  fatigue,  muscle
ache,  tiredness  are  the  most  common symptoms that  cause great  discomfort  to  patients
and most influence their quality of life. They are “carriers” of a deep sufferance but they
have no more own energy to deal with it. It is clear that these people are able to encour‐
age the clinician to work harder in order to match medical experience with psychological
and relational  competence.  They are  also  able  to  lead the  clinician to  overcome the  so-
called “mind-body dichotomy” and get  a  new clinic  view focused on the suffering per‐
son and not just  on the disease.  This aspect  is  really important because it  makes actual
an ethical problem that all health care professionals have to face in everyday clinical life:
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a sterile biological reductionism to the detriment of the centrality of the person [51]. The
Consultation  and  Liaison  Psychiatry  deals  with  the  application  of  psychiatric  theories
and practices for the care of patients with organic disease treated in hospitals and health
care services (e.g., primary care). The request for assistance from colleagues belonging to
other specializations is  so high that  since the mid 70's  specific  consultation-liaison units
have been provided within the departments of psychiatry even more frequently.
Specific  areas  of  Consultation  Psychiatry  include  the  study,  the  diagnosis,  the  treat‐
ment  and  the  prevention  of  psychiatric  morbidity  in  patients  affected  by  organic  dis‐
ease or  somatic  symptoms.
The continuous attention to the phenomena of the organic and psychological interaction
between body and mind is the operative height of the psychiatrist who operates outside the
psychiatric setting [52]. The Consultation and Liaison Psychiatry has been defined as a branch
of psychiatry that focuses on diagnosis, treatment, study and prevention of the psychiatric
morbidity in patients with organic diseases and in those who have somatic symptoms. It also
provides to organize psychiatric consultations, liaison activities and training for non-psychi‐
atric operators who belong to all types of clinical setting, especially in the general hospital [53].
It must be said that the setting of the psychiatrist's intervention is very different from the usual
one, and actually, it consists of a general hospital, inside of which should always be present a
consultation-liaison unit and, inside of it, it must be present an ambulatory for the management
of patients with chronic C hepatitis and IFN treatment or at least, specialized and trained
personnel to the management of this kind of patients.
In  everyday  clinical  practice,  psychiatric  work  consists  of  two  types  of  intervention:
the  psychiatric  consultation  and  liaison.  The  consultation  focuses  primarily  on  diagno‐
sis  and therapy.  The  diagnosis  relies  on  means  such  as  the  clinical  interview and psy‐
cho-diagnostic  tests.
The treatment involves both pharmacologic and psychotherapy interventions.
The specificity of the consultant psychiatrist is therefore, based on his training that allows him
to value the interactions between biological, psychological, social and psychodynamic
variables in clinical practice, in diagnostics, in the treatment plan and prognosis of a mental
disorder [49]. The consultant psychiatrist may also, if he deems it necessary, take charge of the
patient in a continuous way, going beyond the single psychiatric consultation [54]. This
possibility is not uncommon within the psychiatric ambulatories for the management of
patients with HCV in IFN treatment. Many of these patients already have a basic psychiatric
disorder, usually it is a medium degree disorder, never gone to the observation of psychiatrists.
This psychiatric disorder will reoccur or worsen after the diagnosis of HCV or during IFN
treatment, making continuous psychiatric cares necessary. In this regard, it should be said that
patients are hopeful when it is given a chance of cure to them, on the other hand, they are
frightened by the possibility of a therapeutic failure, the length of treatment and the possibility
of serious side effects, including psychiatric symptoms. Actually, patients are really frightened
of these latter symptoms because they have to face the spectrum of madness that, in their
fantasies, drives them to the anguish of losing the ownership of their actions and thoughts.
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Fairly often when they come to the psychiatric interview they feel concerned, sometimes
distrustful. They often hide their fears and try to be light-hearted and cheerful. The classic joke
is: "Doctor, am I mad?
Whatever is the way they face the interview, the spectrum of madness, the anguish of losing
the integrity of their mind, after having already lost their physical integrity, shine through
their words. Sending patients to the psychiatry ambulatory is just a crucial moment. The
hepatologist should always motivate the consultation request, properly informing the patient
about the therapy that he is going to take. What is more, he should inform the patient of the
possible psychiatric side effects, reassuring him at the same time. Reassuring a patient does
not mean to say "do not worry, it's nothing" but it means to be empathetic and show under‐
standing and affectivity to themselves. An empathetic attitude together with clarity of
information and precision to show the therapeutic path, are interventions that reassure
themselves the patient. It is important, therefore, to pursue an empathetic attitude, that is
trying to get as close as possible to emotional experience and the experiences of the other
person, trying to perceive feelings and personal meanings experienced by the patient and
communicate him understanding. Empathic listening is, therefore, a psychological structure
of hospitality that is used to establish trust and strong therapeutic alliance [55].
Clinical experience shows that all patients and, in particular the multi- diagnosed ones, get the
most comfort from knowing that they are at the centre of an integrated and multidisciplinary
system of interventions. Confirming them the importance of their centrality, building around
the patient a set of integrated and coordinated interventions, certainly has positive effects on
collaboration, motivation and, finally, on the outcomes of the interventions.
The Liaison is a more complex and continuous type of intervention, which arises from the
request made by the doctors of department to the psychiatrist or to the clinical psychologist.
It consists of a great collaboration with the treating team that requested the consultation in
order to share the management of the patient's problems. The psychiatrist will discuss with
colleagues from other specialties about therapeutic strategies, he will involve all health
professionals in the care and in the project, he will deal with the relationship problems that
may occur into the staff or between the team and the patient, he will work to promote bio-
psycho-social cultural models within the department. [56] Therefore, interventions addressed
to one or more operators are the true liaison and they can focus on a specific case or on the
overall method of intervention adopted by the consultants. Interventions vary from simple
advice on the attitude to get in the therapeutic relationship to the interpretations of dynamics
that may develop between the patient and the treating team, up to the training programs [57].
Motivations that drive the hepatologist to ask a psychiatric consultation are:
1. a consultation focused on the patient who has already started a therapy with interferon α.
2. a consultation focused on the patient who is “candidate” for a therapy with interferon α.
In the first case, the aim is the one of defining the clinical manifestations and, if possible, the
formulation of the diagnosis and the treatment plan.
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In the second case, they are problematic patients since they have a personal story of psychiatric
disorders, a story of past or current psychopharmacological treatments, a story of abuse or
substance dependence. The consultation, therefore, has the purpose to set the patient from a
diagnostic and personological point of view, in order to support the requesting colleague in
his choice or orientating him towards different treatment choices. The psychiatrist could, for
example, suggest to postpone, if possible, the starting of interferon therapy after an appropriate
period of psychopharmacological treatment or even suggest to avoid interferon therapy. Any
decision must be shared by the patient and, if possible, one member of his family at least. This
kind of patients often needs to be taken in charge by the psychiatric service, for both pharma‐
cological and psychotherapeutic aspects.
It is clear that each component of the medical team will manage the situation with important
ethical implications. The ease of relationship, in terms of respect and recognition of roles,
responsibilities and tasks within the team, is the secret for all health care professionals to take
any decision with greater confidence.
Psychiatric consultation, therefore, can also be directed to the consultant: the patient will not
be visited since the focus is a diagnostic, therapeutic and relational problem.
6. Diagnosis and treatment of mental disorders in patients with HCV
infection during interferon treatment
In the following section we analyse the psychiatric symptoms most frequently found in these
patients.
According to literature, many studies concerning the onset of psychiatric disorders in patients
suffering from HCV, show that depressive symptoms are commonly found despite of the
assumption of antiviral therapy based on Interferon alpha (IFNα) and Ribavirin [58]. It has
been demonstrated that 35% of 293 patients suffering from HCV reported an increase of the
scores of depression even before starting antiviral therapy [59]. Also, it is well known the
interferon α therapy may induce depressive symptoms.
The most important symptoms include: depressive symptoms, anxiety symptoms, cognitive
symptoms, autonomic and somatic symptoms [11].
The autonomic and somatic symptoms tend to occur early during treatment with IFN-α and
persist over time; the symptoms relating to mood, anxiety and cognitive symptoms tend to
occur later during treatment [60,61].
The onset of neuro-vegetative symptoms (e.g. psychomotor retardation) and depressive
symptoms prior to antiviral treatment would increase the likelihood of developing depressive
symptoms [62,63-64,65].
The management of patients with HCV, candidate for therapy with interferon-α, is a vexed
question, considering the prevalence of hepatitis C, the likely presence of problems related to
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substance abuse, the psychological question that the impact of the diagnosis of a disease with
poor prognosis determines and multi-systemic side effects that the therapy itself may cause.
Many studies have shown, in fact, that the impairment of quality of life in these patients is
both linked to the severity of the disease [45] and to the previous substance abuse and side
effects of treatment [66.67 ]. On the other hand, it is also true that interferon therapy, slowing
down and, in some cases, arresting the progression of the disease, could improve the quality
of life of patients suffering from hepatitis C virus [68].
Psychiatric disorders more frequently found in HCV patients treated with interferon α include:
sleep disorders, fatigue, irritability, anxiety disorders, cognitive disorders with impairment of
concentration and memory, depressive episodes (mild, moderate or severe), confusion,
delirium, psychotic disorder, mania, craving (alcohol, drugs). It is worth stressing that
Depression does not just mean deflection of mood; this clinical picture, in fact, is characterized
by a collection of disorders, involving emotional, cognitive and neuro-vegetative changes,
which may occur in several combinations but usually tend to occur all together, resulting in
the so-called depressive spectrum. Some studies have highlighted that depression related to
interferon therapy is significantly different from Major Depression itself. The differences
would involve the ideational sphere mainly. Patients on interferon therapy, in fact, do not
present depressive ideations of guilt and ruin, ideas of inadequacy and worthlessness [69],
typically experienced by patients with major depression. The hypothesis might be that
depression occurring during interferon therapy should be included in the diagnostic category
of "Mood Disorder due to a general medical condition" or "substance-induced disorder",
according to the classification in the DSM IV TR [70 ]. According to the DSM IV TR, in fact, a
Mood Disorder due to a general medical condition, is "a significant and persistent alteration
in mood that is believed to be due to direct physiological effects of a general medical condition",
including degenerative neurological diseases, metabolic conditions, viral infections or other
infections as well. With regards to "Substances-Induced Mood Disorder", this is a condition
that can be induced not only by drugs of abuse but also by medication, toxins. These conditions
are not only characterized by a purely depressive symptomatology but also include symptoms
such as high, expansive or irritable mood. It is shown that manic symptoms [71] and psychotic
disorders [72] may also occur in patients receiving interferon.
It is also interesting to note that cognitive deficits often occur in patients suffering from chronic
hepatitis C [73, 74].
It should also be noted that drug addicts with hepatitis C are affected by psychopathological
alterations to a far greater extent than those who did not abuse substances [75].
In the guidelines of the EASL (European Association for the Study of Liver) [76] it states that
depression is the leading cause of discontinuation of antiviral treatment with interferon α.
According to these guidelines, patients with a documented story of depression should be
evaluated by a psychiatrist before the start of antiviral therapy, so that it could be assessed the
presence of possible psychiatric contraindications. These patients should be followed through‐
out the treatment to find out the onset of depression immediately and then, must be treated
with antidepressants-based pharmacotherapy, when depressive symptoms are recognized.
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Some studies have evaluated the possible use of antidepressants, in particular SSRIs, for
"preventative" purposes, showing actually a reduction in the incidence of depression during
treatment with interferon-α [77].
Regarding the abuse of alcohol, the EASL guidelines recommend not to exclude alcoholic
patients from any antiviral therapy, these patients should receive counselling interventions to
reduce and then stop the consumption of alcohol, as well as psychological support in order to
encourage the compliance with therapies. With regard to addicted patients, guidelines say that
these patients should have stopped the assumption of drugs or should be taking replacement
therapy from 6-12 months. In both cases, it is recommended a close follow up by a multidis‐
ciplinary team composed of the hepatologist, the psychiatrist and the psychologist.
The psychiatrist's figure in a multidisciplinary team for the care of patients with HCV is
therefore essential to evaluate before beginning the treatment: the presence of current anxiety
or depressive episode, history of anxiety or depression or other past psychiatric disorders,
previous psychiatric hospitalisations, history of abuse or dependence on alcohol, drugs and
medication, family history of anxiety disorders, depression or suicide attempts, the presence
or absence of a social support network. Patient must be informed on the risks of psychiatric
symptoms linked to the assumption of IFN-α, showing him all treatment options that are
available in case of psychiatric disorders. If psychiatric disorders were found under way, they
should be treated before starting any antiviral therapy.
Self-administered tests can be used as diagnostic tools for psychiatric assessment, for example,
the Zung Self Rating Depression Scale (ZSDS), the Zung Self Rating Anxiety Scale (ZSAS),
other tests that can be administered are the Hamilton Depression Rating Scale (HAM D) and
the Hamilton Anxiety Rating Scale (HAM A). These tests may be helpful to monitor patient
during therapy.
Regarding any interventions to take in case of psychopathological disorders, such as anxiety
disorders or depressive disorders, it should be said that they must be implemented as early as
possible. The best first choice in treating anxiety disorders is the one of anxiolytics (BDZ).
Among the benzodiazepine, those with little or no hepatic metabolism (oxazepam, lorazepam)
should be chosen. A brief psychotherapeutic intervention may be decisive in case of reactive
anxiety symptoms. SSRIs are the first choice for depressive disorders, especially paroxetine,
sertraline, citalopram, that is, those with the best tolerability profile, the fewer interactions, the
best demonstrated efficiency. If the severity of depressive condition is mild or moderate,
antiviral treatment can be continued. Even in this case psychotherapeutic support interven‐
tions are suggested. If depressive symptoms persist and therapy does not work (by 2-4 weeks),
it should be considered the use of another antidepressant with a different mechanism of action,
or the reduction or discontinuation of IFN treatment; this decision could be made jointly by
the infectious disease specialist, the consultant psychiatrist, the patient and a familiar at least.
If psychotic symptoms occurred, IFN therapy should be discontinued and, if necessary, started
again, only after the patient has been properly treated with antipsychotic drugs.
Depression induced by IFN α responds well to treatment with SSRIs, as it would be mainly
due to alterations involving the serotonergic circuits, while the so-called Neuro-vegetative
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Syndrome induced by IFN, characterized by fatigue, anorexia, pain and psychomotor retar‐
dation, which is often found in association with depressive symptoms, would benefit from
drugs such as SNRIs (venlafaxine) and Bupropion [78].
Confusional episodes characterized by disorientation, somnolence, psychomotor retardation,
psychotic symptoms have also been documented in patients treated with IFN α [79, 80]. In
these cases it is necessary to discontinue therapy and administer neuroleptics or atypical
antipsychotics, including especially olanzapine[81].
It should also be considered the degree of hepatic impairment in these patients in order to
determine the optimal dosage of the drugs. In general, drugs should be used at the lowest
effective dose. It should be pointed out that paroxetine, fluoxetine and fluvoxamine may
reduce the metabolism of other drugs, increasing their blood levels.
It is also useful to consider that some side effects of antidepressants may be exploited for the
patient's benefit; such as weight gain and drowsiness that occurred during treatment with
mirtazapine may be useful in those patients affected by HCV, in which therapy with IFN α
and ribavirin caused hyporexia / anorexia and insomnia.
Another psychiatric symptom that may be found during therapy with IFN α, as already said,
is mania [82,83]. It is important to note that irritability which very often occurs in these patients
is a classic symptom of mania [84]. It seems that manic or hypomanic symptoms develop in
approx. 20% of HCV-positive patients treated with IFN-α and ribavirin [85]. It is very impor‐
tant to recognize dysphoric mania carefully. It is a clinical situation in which both elements
related to manic activation and depressive elements may occur together. The use of antide‐
pressants in dysphoric mania would induce the worsening of the manic picture. Indeed, it is
common that dysphoria may be sometimes confused with a depressive symptom and that is
why the opinion of the psychiatrist should be asked whenever a picture of psychopathological
alterations is suspected.
Finally, we must not forget that interferon therapy may increase the risk of suicide although
studies in this field are still few and results don't appear unique [86, 87]. It is clear that the
prognosis of viral disease itself, which, as well known, can result in cirrhosis and hepatocellular
carcinoma, may cause psychological reactions of despair that can lead to depression and
suicidal ideation. It is worth noting that, according to the DSM IV TR "Mood Disorder due to
a general medical condition increases the risk of suicide attempts and suicide" [1]. Even in case
of suicide then, we must consider several risk factors, ranging from psychological consequen‐
ces of diagnosis and prognosis to depression caused by the therapy.
7. Conclusions
In view of these considerations, it is understandable that the management of patients with
HCV treated or not with IFN α, requires several specialized figures that can deal with the many
aspects that this condition brings with it. The guidelines and literature recommend the
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presence of a multidisciplinary team, in which the psychiatrist plays a key role for the great
incidence of psychiatric disorders in these patients.
In a Consensus Conference held by European specialists in 2005 it was established that, in case
of psychiatric disorders, it is not necessary to delay or forego treatment if this is complemented
by a global care, where several specialists are involved, such as: Gastroenterologist, Infectious
disease specialist, Psychiatrist, Addiction Service Operators, Psychologist – Counsellor [88].
Then, in case of psychiatric disorders, treatment with IFN is strongly recommended, keeping
in mind that the psychological state must be stabilized before starting antiviral therapy.
Some studies have shown that psychiatric disorders may also occur several months after
discontinuation of therapy with IFN α and ribavirin [89], or may still persist even after
discontinuation of therapy [90]. It would be good practice then, that the control of the mental
state of patient continued even after discontinuation of antiviral treatment.
In view of these considerations, it is certain that interferon therapy acts causing mental status
changes that include mainly changes in mood and anxiety. The widespread of C virus is a
ubiquitous problem and therefore, it requires a strong attention that helps to do more and
more to deal with any organic and psychic problems "orbiting" around this condition. It would
be desirable that these patients may have assistance which allows them to continue antiviral
therapy, coping with possible side effects that would probably be a contraindication to
continue therapy, "condemning" the patient to a forced coexistence with the virus.
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